I. Secheli *, M. Secheli *
* Dr. Secheli lonut, medic primar chirurgie pediatrică, Dr. Secheli Marian, medic primar chirurgie pediatrică – Clinica de Chirurgie Pediatrică. Spitalul Clinic de Copii Maria Sklodowska Curie*, București
Abstract
Bleomycin, an antineoplasic peptide antibiotic, DNA strand scission agent, has been recently used in treat ment of vascular anomalies, as a sclerosing agent if it is injected intralesional. We report a study of 42 patients with age between 3 weeks and 15 years, admitted in “Maria Curie” Children Hospital Bucharest in Surgery Depart ment, between 2003 and 2004, treated with Bleomycin intralesional injections. The management of this vascular lesions requires a clear definition and classification. For this reason we used Mulliken and Glowacki biologic classifica tions from 1982 , which gave us possibility to have more precise clinically diagnosis and an acurate evaluation of the treatment. Because of the good results of the intralesional injected of Bleomycin intvascular anomalies – significant improvement in 58% of cases and complete resolution in 34% of cases -, we restricted surgical indication only in a small number of cases . We recomand intralesional injections of Bleomycin as the first line therapy in vas cular lesions – hemangioma and vascular malformations -, as a safe and simple procedure, especially in face and neck region.